Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
Immunovant (IMVT) Stock Price & Analysis
725 Followers
IMVT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.16 - $45.58
Previous Close$26.4
Volume1.38M
Average Volume (3M)1.16M
Market Cap
$3.86B
Enterprise Value$3.22B
Total Cash (Recent Filing)$635.37M
Total Debt (Recent Filing)$138.00K
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Aug 07, 2024EPS Estimate
-$0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.89
Shares Outstanding146,053,941
10 Day Avg. Volume1,197,205
30 Day Avg. Volume1,159,682
Standard Deviation0.24
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)6.46
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-16.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-11.42
Forecast
1Y Price Target
$50.44Price Target Upside83.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Immunovant News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsJNJ presented a data update from the Phase 2 DAHLIAS study with nipocalimab in Sjögren’s disease, showing a dose-response which bodes well for Immunovant given the deep IgG reductions that can be achieved with IMVT-1402 and batoclimab.
Product DevelopmentArgenx is developing a pre-filled syringe formulation of Vyvgart that is expected to be self-administered.
Regulatory ApprovalVyvgart Hytrulo was FDA approved for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP).
Bears Say
Clinical TrialsArgenx will not advance the development of efgartigimod in post-COVID-19-mediated postural orthostatic tachycardia syndrome (PC-POTS) based on negative data from its Phase 2 study.
Data DelaysThe delay of batoclimab Period 1 CIDP data by approximately two quarters, driven by dropouts during the run-in period, is admittedly a bit disappointing.
Patient OutcomesPatients in the 2-week washout are deteriorating more than expected leading to dropouts before bato treatment.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $18.16 and its highest was $45.58 in the past 12 months.
What is Immunovant’s market cap?
Currently, no data Available
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Aug 07, 2024 which is in 35 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on May 29, 2024. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.43 by -$0.09.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -$0.53.
How many shares outstanding does Immunovant have?
Immunovant has 146,180,130 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.43. Following the earnings report the stock price went down -10.687%.
Which hedge fund is a major shareholder of Immunovant?
Among the largest hedge funds holding Immunovant’s share is Perceptive Advisors LLC. It holds Immunovant’s shares valued at 96M.
---
Immunovant Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.44 (83.35% Upside)
$50.44 (83.35% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 85%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
37.93%
12-Months-Change
Fundamentals
Return on Equity
-52.91%
Trailing 12-Months
Asset Growth
64.28%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
---
IMVT Stock 12 Month Forecast
Average Price Target
$50.44
▲(83.35% Upside)
Technical Analysis
Adaptive Biotechnologies
―
Alnylam Pharma
―
Crispr Therapeutics AG
―
Ionis Pharmaceuticals
―
Best Analysts Covering IMVT
1 Year
1 Year Success Rate
10/19 ratings generated profit
1 Year Average Return
+61.12%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +61.12% per trade.
---